• AngioDynamics raised FY 2026 net sales guidance to $313.5 million-$315.5 million from $312 million-$314 million.
• Med Tech net sales growth outlook lifted to 15%-17% from 14%-16%; Med Device growth forecast lifted to about 1% from 0%-1%.
• Adjusted EBITDA outlook increased to $10 million-$12 million from $8 million-$10 million; gross margin outlook unchanged at 53.5%-55.5%.
• Adjusted EPS guidance increased to ($0.30)-($0.23) from ($0.33)-($0.23).
• Cash at Feb. 28, 2026 totaled $37.8 million; cash guidance shifted to slightly negative operating cash flow due to proactive inventory builds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AngioDynamics Inc. published the original content used to generate this news brief on June 10, 2026, and is solely responsible for the information contained therein.